What Has Been The Evolution of the Vaccine Adjuvants Market in Recent Years?
The vaccine adjuvants market has seen considerable growth due to a variety of factors.
•The size of the vaccine adjuvants market has significantly increased over the recent past. The market which stood at $1.89 billion in 2024, is expected to reach $2.03 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.6%.
Factors such as the growth in vaccine development, the widespread of infectious diseases, government-run initiatives and immunization programs, investment in research and development, and the globalization of vaccine distribution have contributed to this historic growth.
What Is the Forecasted Market Size and Growth Rate for The Vaccine Adjuvants Market?
The vaccine adjuvants market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for significant expansion in the vaccine adjuvants market size over the next few years, with projections indicating growth to "$2.89 billion by 2029—and a compound annual growth rate (CAGR) of 9.2%.
Factors contributing to this projected growth during the forecast period primarily include pandemic readiness, expansion of the vaccine portfolio, global vaccination objectives, strategic collaborations and partnerships, and an emphasis on therapeutic vaccines. Major forthcoming trends during this period are predicted to comprise advancements in adjuvant technologies, a stronger focus on enhancing immunogenicity, the use of combined adjuvants for greater effectiveness, a demand for safer and more tolerable adjuvants, as well as personalized vaccines and adjuvants.
What Factors Are Driving Growth In The Vaccine Adjuvants Market?
The growth of the vaccine adjuvants market is anticipated to be driven by the increasing occurrence of infectious diseases. Infectious diseases are those infections caused by pathogens such as viruses, bacteria, fungi, or parasites. These diseases, including hepatitis B (HBV), hepatitis C (HCV), HIV, malaria, syphilis, and brucellosis are treated with vaccines. For example, the World Health Organization (WHO) reported in 2022 that an estimated 10.6 million individuals worldwide contracted tuberculosis in 2021. Additionally, 1.6 million succumbed to it, and roughly 1.5 million people contracted HIV in 2021, with 650,000 fatalities. Therefore, the vaccine adjuvants market can be expected to expand in response to the increasing prevalence of infectious diseases.
What Are The Main Segments Of The Global Vaccine Adjuvants Market?
The vaccine adjuvants market covered in this report is segmented –
1) By Product Type: Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants, Other Product Types
2) By Route of Application: Human Vaccine Adjuvants, Veterinary Vaccine Adjuvants
3) By Route of Administration: Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal
4) By Disease: Cancer, Infectious Diseases, Other Diseases
Subsegments:
1) By Adjuvant Emulsions: Oil-In-Water Emulsions, Water-In-Oil Emulsions
2) By Pathogen Components: Bacterial Components, Viral Components
3) By Particulate Adjuvants: Liposomes, Nanoparticles, Microparticles
4) By Combination Adjuvants: Mixed Emulsions, Multiple Component Systems
5) By Other Product Types: Synthetic Adjuvants, Natural Adjuvants
Pre-Book The Vaccine Adjuvants Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Vaccine Adjuvants Market?
Advances in product development have emerged as a major trend in the vaccine adjuvants industry. Businesses in this sector are focusing their efforts on pioneering new solutions to solidify their standing within the market. For example, in December 2022, Evonik Industries, a chemical manufacturing firm based in Germany, launched PhytoSquene, a plant-based product derived from amaranth oil. This eco-friendly substitute for the conventionally used shark-derived squalene is intended for utilization in vaccine adjuvants and other pharmaceutical applications, improving vaccine effectiveness by amplifying immune responses. The introduction of PhytoSquene highlights the burgeoning focus on sustainability within the pharmaceutical industry.
Who Are the Key Players in the Vaccine Adjuvants Market?
Major companies operating in the vaccine adjuvants market include:
• GlaxoSmithKline Plc.
• Novavax Inc.
• SPI Pharma Inc.
• Agenus Inc.
• CSL Limited
• InvivoGen Limited.
• Brenntag Biosector A/S
• Adjuvatis
• Merck KGaA
• Croda International Plc
• Seppic Inc
• OZ Biosciences
• Avanti Polar Lipids Inc
• Astellas Pharma Inc
• Virometix AG
• MPV Technologies Limited
• Adjuvance Technologies Inc.
• Novartis AG
• Vaxine Pty Ltd
• SBI Biotech Co. Ltd.
• Statens Serum Institute
• GSK Vaccines
• VaxLiant LLC
• VaxForm LLC
• Serum Institute of India
• Dynavax Technologies Corporation
• Vaxcyte Inc.
• VBI Vaccines Inc.
• Medicago Inc.
• Aphios Corporation
What Is The Most Dominant Region In The Vaccine Adjuvants Market?
North America was the largest region in the vaccine adjuvants market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global vaccine adjuvants market report during the forecast period. The regions covered in the vaccine adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
